

Global Vaccine Market Report 2022

November 14, 2022

In news– World Health Organization(WHO) has released the Global Vaccine Market Report 2022 recently.

Key highlights of the report-

- This is the first report to capture the implications of COVID-19 for vaccine markets.
- As per the report, critical vaccines in demand by high-income countries continue to be in short supply for low-income countries.
- Decades-long progress in development, supply and access to doses remains overshadowed by an unfavourable environment.
- The **burden of cervical cancer is higher in low-income countries** in spite of which the human papillomavirus vaccine has been introduced only in 41 percent of these countries.
- In comparison, 83 percent of high-income countries have access to the HPV vaccine.
- The right to health includes the right to vaccines, this new report shows that free-market dynamics deprive some of the world's poorest and most vulnerable people of that right.
- The **COVID-19 vaccine accounted for most of the 16 billion vaccine doses**, worth \$141 billion, supplied in 2021.
- This was a major push for the market – with the volume rising three-fold compared to 2019 and nearly three-and-a-half times the 2019 market value.
- More than 90 manufacturers were supplying vaccines to WHO member states across the world in 2021.
- However, less than 10 managed a bulk of the supply due

to “broad portfolios, global reach and a diversity of deployable technology.”

- **Only two manufacturers are supplying key vaccines such as pneumococcal vaccines, measles and rubella**-containing vaccines across the world.
- Policies and supply chains in specific regions dictate access to vaccines, due to which the African and eastern Mediterranean regions fare the worst.
- These regions rely on international manufacturers for 90 per cent of their procured vaccines.
- The Global Vaccine Market Report listed possible changes which can be made to initiate a paradigm shift in the vaccine market.
- These include: “clear immunisation plans and more aggressive investment and stronger oversight of vaccine development, production and distribution.”